Aging is associated with cognitive decline, and older subjects can have demonstrable cognitive impairment without crossing the threshold for dementia.
This condition has been termed “mild cognitive impairment” (MCI), and these patients have an increased risk of developing dementia, especially Alzheimer disease (AD).
Studies conducted in referral clinics have shown that patients with MCI progress to AD at a rate of 10% to 15% per year, and 80% of these patients have converted to AD after approximately 6 years of follow-up.
The identification and classification of MCI can be a major challenge.
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
topic on dementia covering all aspects regarding classification,pathophysiology and treatment .Difference between MCI and DEMENTIA .best for post graduates ,house officers and medical students
Aging is associated with cognitive decline, and older subjects can have demonstrable cognitive impairment without crossing the threshold for dementia.
This condition has been termed “mild cognitive impairment” (MCI), and these patients have an increased risk of developing dementia, especially Alzheimer disease (AD).
Studies conducted in referral clinics have shown that patients with MCI progress to AD at a rate of 10% to 15% per year, and 80% of these patients have converted to AD after approximately 6 years of follow-up.
The identification and classification of MCI can be a major challenge.
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
topic on dementia covering all aspects regarding classification,pathophysiology and treatment .Difference between MCI and DEMENTIA .best for post graduates ,house officers and medical students
This PPT contains all the important guidelines that are needed to manage a patient of Dementia. It involves diagnosis, psychosocial treatment, non-pharmacological management and pharmacological management. This PPT is prepared from NICE, APA and SIGN guidelines.
A presentation about Alzheimer's disease, it's definition, it's etiology, its mechanism of development as well as actual treatment and developing treatments.
Short presentation about dementia, its types, etiologies, pathophysiologies, treatment, and management. It includes information about vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and Alzheimer's Disease.
SO GUYS ONCE AGAIN HERE I PRESENT U THE OWN MADE PRESENTATION ON THE TOPIC DEMENTIA I HOPE U LIKE THAT IT IS BEEN USEFUL U WHILE MAKING PSYCHIATRIC PRESENTATION
This PPT contains all the important guidelines that are needed to manage a patient of Dementia. It involves diagnosis, psychosocial treatment, non-pharmacological management and pharmacological management. This PPT is prepared from NICE, APA and SIGN guidelines.
A presentation about Alzheimer's disease, it's definition, it's etiology, its mechanism of development as well as actual treatment and developing treatments.
Short presentation about dementia, its types, etiologies, pathophysiologies, treatment, and management. It includes information about vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and Alzheimer's Disease.
SO GUYS ONCE AGAIN HERE I PRESENT U THE OWN MADE PRESENTATION ON THE TOPIC DEMENTIA I HOPE U LIKE THAT IT IS BEEN USEFUL U WHILE MAKING PSYCHIATRIC PRESENTATION
A seminar presentation I'd made for as part of my post-grad psych curriculum. Technically Jung and Alder being here is a problem for some, but it was what the faculty wanted added.
Epidemiology of Alzeimers. Consists of information regarding its global and national burden , its agent ,host and environment ,causes, risk factors and preventive measures to control it.
ALZHEIMER’S DISEASE: IS YOUR POOR MEMORY A WARNING BELL?Meds Engage
Alzheimer’s disease—one of the causative agents of Dementia in the elderly folks is currently the sixth most prominent cause of deaths in America. Dementia results in memory loss, and also affects remembrance, thinking, behavior and cognitive functioning—ultimately hampering the daily routine of the affected person and endangering his or her life.
A complete presentation about all-aspects of the Alzheimer's disease, including Patho Physiology, Treatment, Nursing Management, Prevention, Disease Overview, Clinical Manifestation, etc.
Presentation delivered by Dr. Carol Manning at the live webinar hosted by AlzPossible at www.alzpossible.org on the 17th of March, 2014.
www.alzpossible.org
This is a presentation I did last spring in which I discuss how the OTPF applies to Alzheimer's Dementia. I collected data from scholarly as well as non-scholarly resources. I hope you find this to be helpful.
NIMH i PSC Assays for the Drug Pipeline - Panchisionwef
Dr David Panchision's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
Schizophrenia Research Forum Live Webinar - June 28, 2017 - Rusty Gage wef
Fred Gage's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
Kristen Brennand presentation at the live webinar of June 28, 2017 hosted by the Schizophrenia Research Forum (http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models)
STRATEGIES FOR COMMUNICATION AND SENSITIVITY FOR PERSONS EXPERIENCING DEMENTI...wef
Live presentation recorded June 21, 2017, featuring Ellen Phipps and Devin Bowers - review additional material at www.alzpossible.org/strategies-for-communication/
Translating from Animal Models to Human Schizophrenia - Insights into Pathoph...wef
Presentation made by Dr. Tony Grace at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Presentation made by Dr. Oliver Howes at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Topography and functional significance of the dopaminesgic dysfunction in sch...wef
Presentation made by Dr. Anissa Abi-Dargham at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
SRF Webinar - What It Will Take to Make Coordinated Specialty Care Available ...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
SRF Webinar: Beyond DUP - Addressing Disengagement in Community-based Early I...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
Presentation made March 17, 2017 and hosted by AlzPossible - www.alzpossible.org.
Review recording at http://alzpossible.org/webinars-2/the-basics-memory-loss-dementia-and-alzheimers-disease/
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
HEAR approach to behavior management Live webinar Feb 1 2017wef
Slides presented at the HEAR Approach to Behavior Management live webinar of February 1, 2017, featuring presentations from Dr. Andrew Heck and Carol Garby.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
1. Recommended pre-requisite presentation for
“The Other Dementias: Virtual Training and Active Learning on Non-Alzheimer’s
Dementias”
three-part series, which is made possible through a grant funded from
2. TYPICAL CHANGES
• Making a bad decision once in a while
• Missing an occasional monthly payment
• Forgetting which day it is and remembering
later
• Sometimes forgetting which word to use
• Losing things from time to time
A-TYPICAL CHANGES
• Consistent poor judgment and decision
making
• Loss of an ability to manage money
• Inability to keep track of the date or the
season
• Difficulty having a conversation
• Misplacing things and loss of the ability to
retrace steps to find them
3. There are many
causes of dementia
symptoms.
Is NOT a specific disease.
Alzheimer's disease is
the most common cause
of a progressive
dementia.
Is a GROUP OF SYMPTOMS
affecting intellectual and social abilities
severely enough to interfere with daily
functioning.
Memory loss generally occurs in
dementia, but memory loss alone does
not imply you have dementia.
7. Alzheimer’s
disease is more
prevalent among
African-Americans
than among whites
Estimates range
from 14% to
almost 100%
higher;
There is a greater
familial risk of
Alzheimer’s in
African-Americans
The cumulative
risk of dementia
among firstdegree relatives
of AfricanAmericans who
have Alzheimer’s
disease is 43.7%
Genetic and environmental factors may work differently
to cause Alzheimer’s disease in African-Americans
Data from a large-scale longitudinal study indicate that persons
with a history of either high blood pressure or high cholesterol
levels are twice as likely to get Alzheimer’s disease. Those with
both risk factors are four times as likely to become demented.
65% of African-American Medicare beneficiaries have
hypertension, compared to 51% of white beneficiaries.
They are also at higher risk of stroke.
(Data from the Current Medicare Beneficiary Survey)
African-Americans have a 60% higher risk of type 2 diabetes —
a condition that contributes directly to vascular disease.
African-Americans have a higher rate of vascular dementia than
white Americans.
http://www.alz.org/national/documents/report_africanamericanssilentepidem
8. Brain
disorder,
most
common
form of
dementia
Affects
5% of
people at
age 65
Affects
50% of
people
age 85+
ASSOCIATED RISK FACTORS:
•
•
•
•
•
•
•
•
•
•
TREATMENT:
•
•
Late-onset
(65+) is
most
common, s
lowestprogressin
g
Average
course of
DAT: 6-20
years
Age
Family history
Down syndrome
Incidence higher in women
Alcohol use
Atherosclerosis
Blood pressure
Cholesterol
Depression
Diabetes (type 2)
•
•
No treatment available to slow or stop the deterioration of
brain cells in Alzheimer's disease.
US FDA has approved five drugs that temporarily slow
worsening of symptoms for about 6 - 12 months.
Effective for only about ½ of the individuals who take them.
Inconclusive research:
Vitamin E
Anti-inflammatory drugs
Estrogen
Vaccine
Diet
INCIDENCE: AD more prevalent among African-Americans
and Hispanics
10. Memory loss that
disrupts daily
functioning
Challenges in
planning or solving
problems
Changes in mood and
personality
Withdrawal from work
or social activities
Difficulty completing
familiar tasks at
home, at work or at
leisure
Decreased or poor
judgment
Confusion with time
or place
Trouble
understanding visual
images and spatial
relationships
Misplacing things and
losing the ability to
retrace steps
New problems with
words in speaking or
writing
11. VaD can be
cortical and
subcortical
2nd most
common
dementia
after
Alzheimer's
disease
Result of a
damage to
the brain
caused by
problems
with the
arteries
serving the
brain or
heart.
Approx. 2530% of all
dementias
are VaD
Prevalence
of VaD
ranges
from 1 to 4
percent in
people over
the age of
65.
CAUSES:
• Untreated high blood pressure
• Diabetes
• High cholesterol
• Heart disease
ASSOCIATED SYMPTOMS:
• Confusion and agitation; depression
• Unsteady gait
• Problems with memory
• Urinary
frequency, urgency, incontinence
• Night wandering
• Decline in ability to organize
thoughts/actions, difficulty planning
• Poor attention/concentration
TREATMENT:
Damage caused by infarcts cannot be
reversed. Future cerebrovascular
incidents can be controlled (control of
cardiovascular risk factors)
12. Pick's disease
affects parts of the
brain that contain
fibrous tangles
made up of an
abnormal protein
called tau protein
Group of
diseases
characterized
by the
degeneration
of nerve cells
in the F-T
areas of the
brain
Begins earlier
and
progresses
faster than
AD
Occurs at
ages younger
than AD, i.e.,
40-70.
One form of
this condition
is Pick's
disease.
(Fronto-temporal
areas of the brain are
generally associated
with
personality, behavior
and language). In
these
dementias, portions
of these lobes
atrophy.
CAUSES:
• Unknown
• Possible genetic mutations.
ASSOCIATED SYMPTOMS:
• socially inappropriate behaviors
• loss of mental flexibility
• decline in personal hygiene
• language problems, and
• movement disorders
• difficulty with concentration and
thinking.
13. CJD is a
degenerative
brain
disorder that
leads to
dementia
and,
ultimately,
death. (rapid
progression)
Variant CJD is
linked primarily to
eating beef
infected with
bovine
spongiform
encephalopathy
(mad cow
disease.
The "classic"
CreutzfeldtJakob
disease has
not been
linked to
contaminated
beef.
1 in 1 million
people are
diagnosed
with CJD per
year (usually
older adults).
CAUSES:
abnormal versions of a protein called a
prion.
TRANSMISSION
Risk of CJD is low.
Cannot be transmitted through
coughing, sneezing, touching or sexual
contact.
CJD DEVELOPS:
• Spontaneously (majority of cases)
• Genetic mutation (family history)
• Contamination. (very low number of
exposures to infected human tissue
during a medical procedure)
ASSOCIATED SYMPTOMS:
personality
changes, anxiety, depression, memory
loss, impaired thinking, blurred
vision, insomnia
difficulty swallowing, motor issues.
15. Deposition
of Lewy
bodies in
both,
cortical and
subcortical
Has features
of both PD
and AD
Affects 1%
of those age
65, 5% over
age 85
Usually
progresses
more rapidly
than DAT
(average = 6
years)
16. PD is a
progressi
ve
disorder
of the
CNS
Results
from a
deficiency
in the
neurotran
smitter
DOPAMIN
E
Affects
more than
1.5 million
people in
the US
20-40%
have
more
severe
symptom
s/
dementia
50%+ of
people
with PD
have MCI.
19. Educational programs for
families and professionals
1-800 272-3900
The Alzheimer's Association is the leading voluntary health
organization in Alzheimer’s, care, support and research.
Its mission is to eliminate Alzheimer’s disease through the
advancement of research; to provide and enhance care
and support for all affected; and to reduce the risk of
dementia through the promotion of brain health.
•
•
•
•
•
•
24-hour Helpline
Information and referrals
Care consultation
Support groups
Online community
Safety services
www.alz.org
21. Virginia Easy Access is a FREE resource providing a simple method to search for specific services anywhere
in Virginia. Virginia Easy Access is a gateway to VirginiaNavigator (which lists over 21,000 programs and
services throughout the Commonwealth) and to the 2-1-1 Virginia Call Center.
easyaccess.virginia.gov
Hello. Today we are going to discuss Alzheimer’s disease briefly, but focus on the “other” dementias. This is a brief overview rather than an in-depth study.
Many people worry about becoming more forgetful as they grow older. Our brains change as we age, just like the rest of our bodies. We all misplace our keys once in a while; we all enter a room forgetting why we went there in the first place. Does this mean we have “dementia”? Probably not. Serious memory loss, confusion, and other major changes in the way our minds work are not typical parts of aging. Many conditions can disrupt memory and mental function. If symptoms such as consistent poor judgment; inability to manage money; difficulty with keeping track of date or time; difficulty conversing; or misplacing things but unable to retrace steps are noticed – it is time to see a doctor. Symptoms that interfere with daily function should be addressed. However, keep in mind, there are many causes for symptoms, some causes can be treated. And that is why it is important to be checked out by a physician.
There is often confusion with terms. So, to begin let’s take a look at Dementia. Dementia is actually an umbrella term describing a variety of diseases and conditions that develop when nerve cells in the brain (called neurons) die or no longer function normally. The death or malfunction of neurons causes changes in one’s memory, behavior and ability to think clearly.
Physicians often define dementia based on the criteria given in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).(1) To meet DSM-IV criteria for dementia, the following are required: • Symptoms must include decline in memory and in at least one of the following cognitive abilities:1) Ability to speak coherently or understand spokenor written language.2) Ability to recognize or identify objects, assumingintact sensory function.3) Ability to perform motor activities, assumingintact motor abilities and sensory function andcomprehension of the required task.4) Ability to think abstractly, make sound judgmentsand plan and carry out complex tasks.• The decline in cognitive abilities must be severeenough to interfere with daily life.
To establish a diagnosis of dementia, a physician must determine the cause of the dementia-like symptoms. Some conditions have symptoms that mimic dementia but that, unlike dementia, can be reversed with treatment – such as those listed here. In contrast, dementia is caused by irreversible damage to brain cells.
Alzheimer’s disease, a progressive, degenerative disease of the brain, was first identified more than 100 years ago, but research into its symptoms, causes, risk factors and treatment has gained momentum only in the last 30 years. Although research has revealed a great deal about Alzheimer’s, the precise changes in the brain that trigger the development of Alzheimer’s, and the order in which they occur, largely remain unknown. The only exceptions are certain rare, inherited forms of thedisease caused by known genetic mutations.
AD IS Most common type of dementia; accounts for an estimated 60 to 80 percent of cases. Difficulty remembering names and recent events is often an early clinical symptom; apathy and depression are also often early symptoms. Later symptoms include impaired judgment, disorientation, confusion, behavior changes and difficulty speaking, swallowing and walking. New criteria and guidelines for diagnosing Alzheimer’s were proposed in 2011. They recommend that Alzheimer’s disease be considered a disease that begins well before the development of symptoms.Hallmark brain abnormalities are deposits of the protein fragment beta-amyloid (plaques) and twisted strands of the protein tau (tangles) as well as evidence of nerve cell damage and death in the brain.
Add notes…
Previously known as multi-infarct or post-stroke dementia, vascular dementia is less common as a sole causeof dementia than is Alzheimer’s disease. Impaired judgment or ability to make plans is more likely to be the initial symptom, as opposed to the memoryloss often associated with the initial symptoms of Alzheimer’s. Vascular dementia occurs because of brain injuries such as microscopic bleeding and blood vessel blockage. The location of the brain injury determines how the individual’s thinking and physical functioning are affected. In the past, evidence of vascular dementia was used to exclude a diagnosis of Alzheimer’s disease (and vice versa). That practice is no longer considered consistent with pathologic evidence, which shows that the brain changes of both types of dementia can be present simultaneously. When any two or more types of dementiaare present at the same time, the individual is considered to have “mixed dementia.”
Includes dementias such as behavioral variant FTLD, primary progressive aphasia, Pick’s disease and progressive supranuclear palsy.Typical symptoms include changes in personality and behavior and difficulty with language. Nerve cells in the front and side regions of the brain are especially affected. No distinguishing microscopic abnormality is linked to all cases. The brain changes of behavioral variant FTLD may be present at the same time as the brain changes of Alzheimer’s, but people with behavioral variant FTLD generally develop symptoms at a younger age(at about age 60) and survive for fewer years than those with Alzheimer’s.
Rapidly fatal disorder that impairs memory and coordination and causes behavior changes. Results from an infectious misfolded protein (prion) that causes other proteins throughout the brain to misfold and thus malfunction. Variant Creutzfeldt-Jakob disease is believed to be caused by consumption of products from cattle affected by mad cow disease.
Mixed dementia is characterized by the hallmark abnormalities of AD and aother type of dementia – most commonly, vasuclar dementia, but, also, other types – such as dementia with lewy bodies. Recent studies suggest that mixed dementia is more common than previously thought.
People with DLB have some of the symptoms common in Alzheimer’s, but are more likely than people with Alzheimer’s to have initial or early symptoms such as sleep disturbances, well-formed visual hallucinations, and muscle rigidity or other parkinsonian movement features. Lewy bodies are abnormal aggregations (or clumps) of the protein alpha-synuclein. When they develop in a part of the brain called the cortex, dementia can result. Alpha-synuclein also aggregates in the brains of people with Parkinson’s disease, but the aggregates may appear in a pattern that is different from DLB.The brain changes of DLB alone can cause dementia, or they can be present at the same time as the brain changes of Alzheimer’s disease and/or vascular dementia, with each entity contributing to the development of dementia. When this happens, the individual is said to have “mixed dementia.”
As Parkinson’s disease progresses, it often results in a severe dementia similar to DLB or Alzheimer’s. Problems with movement are a common symptom early in the disease. Alpha-synuclein aggregates are likely to begin in an area deep in the brain called the substantianigra. The aggregates are thought to cause degeneration of the nerve cells that produce dopamine. The incidence of Parkinson’s disease is about one-tenth that of Alzheimer’s disease.